Pyronaridine-Artesunate versus Mefloquine plus Artesunate for Malaria

Abstract

Background: Pyronaridine–artesunate is an artemisinin-based combination therapy under evaluation for the treatment of Plasmodium falciparum and P. vivax malaria.

Methods: We conducted a phase 3, open-label, multicenter, noninferiority trial that included 1271 patients between 3 and 60 years of age from Asia (81.3%) or Africa (18.7%) with microscopically confirmed, uncomplicated P. falciparum malaria. Patients underwent randomization for treatment with a fixed-dose combination of 180 mg of pyronaridine and 60 mg of artesunate or with 250 mg of mefloquine plus 100 mg of artesunate. Doses were calculated according to body weight and administered once daily for 3 days.

Results: Pyronaridine–artesunate was noninferior to mefloquine plus artesunate for the primary outcome: adequate clinical and parasitologic response in the per-protocol population on day 28, corrected for reinfection with the use of polymerase-chain-reaction (PCR) genotyping. For this outcome, efficacy in the group receiving pyronaridine–artesunate was 99.2% (743 of 749 patients; 95% confidence interval [CI], 98.3 to 99.7) and that in the group receiving mefloquine plus artesunate was 97.8% (360 of 368 patients; 95% CI, 95.8 to 99.1), with a treatment difference of 1.4 percentage points (95% CI, 0.0 to 3.5; P=0.05). In the intention-to-treat population, efficacy on day 42 in the group receiving pyronaridine–artesunate was 83.1% (705 of 848 patients; 95% CI, 80.4 to 85.6) and that in the group receiving mefloquine plus artesunate was 83.9% (355 of 423 patients; 95% CI, 80.1 to 87.3). In Cambodia, where there were 211 study patients, the median parasite clearance time was prolonged for both treatments: 64 hours versus 16.0 to 38.9 hours in other countries (P
Conclusions: Fixed-dose pyronaridine–artesunate was efficacious in the treatment of uncomplicated P. falciparum malaria. In Cambodia, extended parasite clearance times were suggestive of in vivo resistance to artemisinin.

Citation

Rueangweerayut, R.; Aung Pyae Phyo; Uthaisin, C.; Poravuth, Y.; Tran Quang Binh; Tinto, H.; Pénali, L.K.; Valecha, N.; Nong Thi Tien; Abdulla, S.; Borghini-Fuhrer, I.; Duparc, S.; Shin, C.S.; Fleckenstein, L. Pyronaridine–Artesunate versus Mefloquine plus Artesunate for Malaria. New England Journal of Medicine (2012) 366 (14) 1298-1309. [DOI: 10.1056/NEJMoa1007125]

Pyronaridine-Artesunate versus Mefloquine plus Artesunate for Malaria

Help us improve GOV.UK

Don’t include personal or financial information like your National Insurance number or credit card details.